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Opinion statement
The management of patients with unprovoked venous thromboembolism is a com-
mon and challenging clinical problem. Although the initial antithrombotic manage-
ment is well-established, there is uncertainty about the optimal long-term
anticoagulant management, specifically whether patients should receive a short
(i.e., 3- to 6-month) duration of anticoagulant therapy or indefinite anticoagula-
tion. Factors that may be considered to estimate patients' risk for recurrent throm-
boembolism include the mode of initial clinical presentation, as deep vein
thrombosis or pulmonary embolism, patient sex, antecedent hormonal therapy
use, thrombophilia, D-dimer levels, and residual vein occlusion in patients with
deep vein thrombosis. Many of these factors have been integrated into clinical pre-
diction guides which stratify patients with unprovoked venous thromboembolism
according to their risk for disease recurrence and, thereby, can assist clinicians
in decisions about the duration of anticoagulation. The objective of this review
is to consider the evidence relating to the clinical significance of purported risk
factors and provide a practical case-based approach to guide decisions on duration
of anticoagulation for patients with unprovoked venous thromboembolism.
Introduction
The management of patients with venous thromboem-
bolism (VTE) should reflect the biphasic, acute and
chronic, nature of this disease [1•]. In the acute phase,
the overall treatment aim is to reduce symptoms relat-
ed to deep vein thrombosis (DVT) and pulmonary em-
bolism (PE) and to prevent thrombus extension and
(additional) embolization, the latter of which can in-
crease mortality [2–4]. This can be done with prompt
initiation of anticoagulant therapy [5••]. The initial
phase of anticoagulation aims also to prevent exten-
sion of asymptomatic DVT, which occurs in 20 % of
patients presenting with symptomatic PE alone, and
to prevent recurrent PE, which is present but silent
in up to 50 % of patients presenting with DVT alone
[6]. Minimizing the risk for DVT progression or recur-
rent PE is important to mitigate the risk that patients
will develop the post-thrombotic syndrome [7] and
chronic thromboembolic pulmonary hypertension
[8], and to prevent recurrent VTE that is fatal.
After this initial treatment, the aim of anticoagulant
therapy is to minimize the risk for disease recurrence
since the occurrence of a first VTE markedly increases
the risk for further VTE [6,9]. Vitamin K antagonist
therapy, typically with warfarin, is highly effective in
reducing the risk for recurrent VTE [10,11]. Although
this clinical benefit is not maintained after treatment
d i s cont inua t ion , r ega rd le s s o f i t s dura t ion
[11,12,13••], the benefit of continued anticoagulation
needs to be balanced against the risk for anticoagu-
lant-related bleeding [14]. Given the effectiveness of
anticoagulants to prevent recurrent VTE (as summa-
rized in Table 1), the challenge facing the clinician is
to identify which patients would derive a net clinical
benefit from indefinite anticoagulant therapy and
those in whom avoidance of long-term anticoagula-
tion is preferable.
It is widely accepted that three months of anticoa-
gulation is sufficient for most patients with a first VTE
that occurs in association with a major transient risk
factor such as surgery, lower limb fracture or other
trauma, pregnancy, and immobilization [5••,15••].
For these patients, the risk of recurrent VTE after three
months of anticoagulation is lower compared with a
shorter duration of treatment but there is no therapeu-
tic advantage to longer treatment duration [13••]. Such
patients have a good prognosis, with a 1–3 % person-
year risk for recurrent VTE [15••]. Patients who develop
VTE in association with a weak risk factor, such as estro-
gen use or long-distance travel, appear to have a slightly
higher risk for recurrence [15••] but three months of
anticoagulation also is sufficient in such patients. Final-
ly, patients who develop VTE in association with active
cancer warrant consideration for indefinite anticoagula-
tion [5••].
In contrast, there is uncertainty about optimal
management for patients with unprovoked VTE, who
comprise approximately 50 % of all patients with a
first VTE. In such patients who have received three
months of anticoagulation, the risk for recurrent VTE
is 5–15 % per year after anticoagulation is stopped
[15•• ,16•], or up to 30–35 % after five years
[16•,17••, 18], and this recurrence risk is not affected
by whether patients receive an additional 3–9 months
of anticoagulation [13••]. Stated differently, patients
with unprovoked VTE who are destined to develop
disease recurrence will do so irrespective of the dura-
tion of anticoagulation. When considered against a
1–3 % annual risk for anticoagulant-related bleeding
[14], the net therapeutic benefit would seem to favor
administering indefinite anticoagulation in all patients
with unprovoked VTE. However, rather than subject
all such patients to the risks and costs of indefinite
anticoagulation, the challenge for the clinician is to
identify patients who are most likely to develop recur-
rent VTE, in whom indefinite anticoagulation can be
justified, and those patients with an acceptably low
risk for recurrence in whom anticoagulation can be
stopped.
Against this background, the objectives of this re-
view are: 1) to summarize, risk factors and clinical
prediction guides (CPGs) that can be used to esti-
mate patients’ risk for recurrence after a first unpro-
voked VTE; and 2) to suggest a management strategy
to help guide decisions of whether to recommend
3–6 months or indefinite anticoagulation in such
patients. Three representative case vignettes will be
considered to help illustrate the suggested clinical
approach:
& 58 year old man, otherwise well, with a first
unprovoked PE (D-dimer not available);
& 35 year old woman, otherwise well, with a first
PE occurring during oral contraceptive use;
& 82 year old woman, with co-morbidities, and a
first unprovoked DVT (D-dimer available)
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In Table 2 and Fig. 1 we provide a suggested
approach to the management of these cases based
on the available evidence and practical considera-
tions.
Table 1. Pharmacologic treatment options
Drug [ref]‡ Standard dosage and timing Comments






80 U/kg bolus i.v., then 18 U/kg/h
(or 5,000 U i.v. then 1000 U/h),
adjusting infusion velocity to reach a
PTT target 1.5-2.5 times normal
- When thrombolytic therapy is planned, UFH is
recommended over LMWH or fondaparinux





Enoxaparin: 1 mg/kg s.c. twice a day 1. Long-term (6 months) treatment with heparin
(1 month of full dose followed by 5 months of
reduced dose to 75 %) was demonstrated to be
more effective than warfarin only in patient
with VTE and cancer.
Enoxaparin: 1.5 mg/kg s.c. once daily
2. If renal impairment (calculated creatinine
clearance G30 ml/min), consider UFH.
Tinzaparin: 175 U/kgs.c. once daily
Dalteparin: 200 U/kg s.c. once daily
Fondaparinux
[5••,95]
7.5 mg s.c. once daily (or 5 mg once
daily if body weight G50 kg; 10 mg
once daily if G if body weight 9100 mg)








Warfarin: loading dose of 5 or 10 mg
for first 2 days then dosing based




1. In patients with acute VTE, warfarin should
be started early together with parenteral
anticoagulation which should be given for at
least 5 days while waiting for therapeutic INR
2. Low-intensity warfarin (target 1.5-2) after a
first full-dose treatment (for at least
3 months) may reduce recurrences but is less
effective than full-dose warfarin
Rivaroxaban∫
[5••,97,98]
15 mg orally twice a day for 3 weeks
and then 20 mg once daily
20 mg once daily In patients who receive rivaroxaban for
acute VTE, there is no requirement for
initial treatment with UFH or CMWH
Dabigatran∫
[5••,99]
150 mg orally twice a day 150 mg twice a day 1. In the acute phase, dabigatran should be
started after/in association to an initial
treatment with LMWH or UFH for the first few
days after diagnosis 2. No evidence on
long-term/extended anticoagulation (no more
than 6 months) with dabigatran for VTE.
Aspirin
[93,94••]
- 100 mg orally
once daily
Possible option in patients not at high risk
of recurrence
** 9 3 months treatment (current guidelines recommend extended anticoagulation to continue on the same drug used for long-term treat-
ment if there is not any specific reason for switching). ‡We refer to evidence summarized in the 2012 ACCP Antithrombotic Clinical Practice
Guidelines. ∫Rivaroxaban and dabigatran are not yet approved for clinical use for venous thromboembolism in the United States
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predictors of risk of
recurrence
Recurrent risk estimates
(annualized risk [AR] or
cumulative rate [CR])
according to available CPGs∫
Conclusion and notes




Male sex: 1.5-2 fold higher risk
compare to females
[16••,20,22,23••,24–28]
Men and HER-DOO-2 [82]:
AR 93 %
High risk patient
PE as first presentation:
higher risk compared to




presenting initially with PE
more likely to have
recurrence as PE than DVT
[12,30•,33,87]
Vienna [17••]: if D-dimer
was available, the opposite
scenario would be:
Note: 1.Measuring D-dimer level
would help but this is a high risk
case independently of D-dimer.
2. If the same patient had
presented with a first proximal
DVT, his risk predicted by Men
and HER-DOO-2 and DASH score
would not change and would




D-dimer 100 ng/ml→CR 4.3 %
(2.7-6.9) at 1 year, 15.6 %
(10.3–23.2) at 5 years
D-dimer 2000 ng/ml→CR
10.5 % (7.3–15) at 1 year,
34.7 % (26.5–44.4) at
5 years
DASH[84••]: score from 2
to 4→AR 7–20 % (for
patients presenting with
PE, CR of recurrence as PE
of 10.6 % at 5 years [30•])





Women with a hormone-
related VTE: a lower
(nearly 0.5) risk compared
to women with a first
unprovoked not-hormone-
related VTE, if exposure
to hormone therapy risk
comparable to VTE provoked
by nonsurgical transient risk
factor [15••,16••,21,22,23••]
Men and HER-DOO-2 [82]:
AR9 or G3 % depending on
presence or not of at least 2
of: obesity, signs of
post-thrombotic syndrome,
D-dimer≥250 mg/dl [the
estimate of AR for women
with an OC-related VTE at
high risk according to the
score was largely imprecise:
4.1 % (0–12.2) ][100]
Low risk patient
Vienna [17••]: not applicable
DASH [84••]: score from -2 to
0→AR G3 %
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Clinical and laboratory risk factors for recurrent VTE
Treatment guidelines such as the 2012 American College of Chest Physi-
cians (ACCP) Antithrombotic Guidelines [5••] do not provide recom-
mendations for using risk factors or CPGs to decide on the duration
of anticoagulation for individual patients after unprovoked VTE, though
it is suggested that these factors be considered in the decision-making
process [5••]. Herein, we shall review factors for which there is a clini-
cally meaningful body of evidence regarding their role in estimating the
risk of recurrent VTE whereas other clinical factors, such as age and obe-
sity, and other laboratory markers, for which there is a paucity of evi-
dence, will not be reviewed.




predictors of risk of
recurrence
Recurrent risk estimates
(annualized risk [AR] or
cumulative rate [CR])










lower risk compare to
males [16••,20,22,
23••,24–28]
Men and HER-DOO-2 [82]: 1
point for age→AR 9 or G 3 %
depending on presence or not




Proximal DVT as first
presentation: a higher risk
compared to distal DVT;
probably not significant
difference respect to PE
[12,13••,30•,31–33]
Vienna [17••]: CR range
according to D-dimer level:
Note: Although the prognostic
validity of D-dimer holds
regardless of patient comorbiity,
the presence of multimorbidity
affects the decision process since
a) it can increases the patient risk
of bleeding; b) the decision on
extended anticoagulation may
cross other therapeutic needs
Age: not definitive evidences
[16••,17••,84••]
D-dimer 100 ng/ml→CR
2.0 % (1.1–3.7) at 1 year,
7.6 % (4.3-13.3) at 5 years
D-dimer after stopping
anticoagulation: strong
predictor of risk independent
of age and comorbidity
[16••,65–73]
D-dimer 2000 ng/ml→5.1%
(3.3-7.8) at 1 year, 18.1 %
(12.5-25.8) at 5 years
DASH [85]: score from
1 to 3 according to
D-dimer level → AR 2.9-
13.4 %
M, male; F, female; OC, oral contraceptive; VTE, venous thromboembolism; PE, pulmonary embolism; DVT deep vein thrombosis; CPG, clin-
ical prediction guide
‡Patients have received 3–6 months of anticoagulation. ∫None of CPGs externally validated
228 Vascular Disease (H Gornik and E Kim, Section Editors)
Estrogens and patient gender
High levels of estrogen, whether occurring during pregnancy and the puerpe-
rium or with oral contraceptive or estrogen replacement therapy use, increase
Fig. 1. Case examples: suggested strate-
gies for a long-term management.
Legend. The vignette synthesizes the
suggested treatment strategies for the
clinical cases proposed as example of
patients at high, low and intermediate
risk, joining the evidence summarized in
Table 2 with other relevant aspects of the
clinical decision making process. (Thanks
to Nebbiai Mattia for the drawing).
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the risk for VTE [19]. Women who continue hormonal therapy after a hor-
mone-related VTE have a 5-fold increased risk of recurrent VTE [20]. Con-
versely, women who stop hormonal therapy after VTE have a 50 % lower
risk for recurrence than women with unprovoked (not hormone-related)
VTE [15••,16•,21,22,23••]. From an absolute risk perspective, women
who stop hormonal therapy after VTE have an approximately 4 % annual risk
of disease recurrence, which is slightly higher than after surgery-related VTE
but similar to the recurrence risk when VTE occurs in association with
non-surgical transient risks such as immobilization or long-distance travel
[15••,21]. Estrogen exposure may also explain the observed difference in
the risk for recurrent VTE between men and women. After discordant findings
reported in individual studies [20,22,24–27], a study-level meta-analysis [28]
and a large patient-level meta-analysis [16•,23••] found that in patients with
unprovoked VTE, men had a 1.5-to-2.0-fold higher risk for recurrent VTE
than women. Thus, male patients who are treated for three months after a
first unprovoked VTE have a 3-year risk of recurrence as high as 20–25 %
[23••].
Clinical presentation and extent of venous thrombosis
Although DVT and PE are manifestations of the same disease, the mode of
clinical presentation and the extent of thrombosis may affect patient progno-
sis. Thus, patients with distal (calf) DVT have a 2.5 % annual risk of recur-
rence after three months of anticoagulation, which is 2-to-4-fold lower
than patients with proximal DVT and/or PE [6,10,13••,29,30•]. Whereas
some discrepant findings were reported for patients presenting with PE com-
pared to patients presenting with DVT alone [12,31–33], two independent
patient-level meta-analyses found no difference in rates of recurrent VTE, irre-
spective of initial presentation as DVT or PE [13••,30•]. However, patients
presenting with PE are more likely to develop recurrence manifesting as PE
than as DVT [12,30•,32,33] and, consequently, are at increased risk that re-
currence will be life-threatening or will lead to chronic pulmonary hyperten-
sion. The ACCP Guidelines recommend the same anticoagulant therapy
management in patients presenting with PE or isolated proximal DVT [5••].
Hereditary thrombophilic defects
The factor V Leiden and prothrombin gene mutations are the most common
prothrombotic genetic abnormalities occurring in patients with VTE [34]. De-
ficiencies of endogenous anticoagulants (antithrombin, protein C, protein
S), high levels of factor VIII and XI, and hyperhomocysteinemia are other,
less common, hereditary thrombophilic defects [34]. One or more of these
abnormalities occur in up to 50 % of patients with a first unprovoked VTE
[20,35,36] but there is a weak or non-significant association between these
abnormalities and the development of recurrent VTE [35,37–46]. Prospective
studies have not shown that testing for thrombophilia can predict the long-
term risk of recurrent VTE, especially after adjusting for stronger predictors
such as the absence of an antecedent provoking risk factor [20,21], and no
studies have shown that management strategies based on thrombophilia test-
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ing affect patients’ risk for recurrence [47]. Furthermore, there is no known
relation between a family history of VTE and the likelihood of detecting a
thrombophilic abnormality [48]. For these reasons, routine screening for
inherited thrombophilia is not recommended in patients with unprovoked
VTE as it will not have a major impact on the duration of anticoagulation
[5••,49,50]. In selected patients testing for thrombophilia may assist in their
counseling about prognosis, but the implications of the test results should be
clearly discussed with patients before testing is done [49–51].
Laboratory testing for lupus anticoagulant, anticardiolipin antibodies and
anti-α2 glycoprotein-I antibodiesmerits special consideration since usually they
are not inherited abnormalities. It is difficult to estimate their prevalence in the
general population because of the potential for false positive test results, espe-
cially when a positive test is not confirmed with repeat testing and at a time re-
mote from the acute VTE [35,52–54]. The clinical significance of individual tests
is uncertain, in part because of different laboratory assays and criteria for test
positivity. However, in one well-designed study involving patients with prior
VTE (who stopped anticoagulation), a positive anticardiolipin antibody or lu-
pus anticoagulant conferred a 2-fold higher risk of recurrent VTE than patients
with a negative test [55]. Overall, a diagnosis of the antiphospholipid syndrome
should be made carefully, requiring the combination of clinical and laboratory
criteria [56]. Moreover, positive laboratory tests should be confirmed with re-
peat testing done at least six weeks apart and at a time remote from the index
VTE or other acute illnesses. If this diagnosis is confirmed, it has important clin-
ical implications because of the high risk for recurrent VTE if anticoagulation is
stopped.
Residual vein occlusion
In patients with proximal DVT, the presence of a residual vein occlusion
(RVO) identified by venous ultrasound three or more months after diagnosis
may identify patients at increased risk for recurrent VTE. Some studies found
that patients with RVO, whether occlusive or non-occlusive, are at increased
risk for recurrent VTE compared with patients in whom there is complete
vein recanalization [57–59]. In three randomized trials [60–62] that explored
the benefit of extended anticoagulation in patients with RVO after 3–
6 months of anticoagulation for DVT found a higher rate of recurrence in
patients with RVO than in those without RVO. On the other hand, a pa-
tient-level meta-analysis suggested that RVO was a weak predictor of recur-
rence after unprovoked VTE and that the association between RVO and
recurrence was stronger if RVO was detected early (within three months)
than later (96 months) after diagnosis [63]. The use of RVO to assess recur-
rence risk is limited by the lack of a standard definition for RVO and the poten-
tial for operator variability in the interpretation of ultrasound findings [64].
D-dimer
D-dimer, a fibrin degradation product, which is used to assess patients with
suspected DVT or PE, has been also studied as a predictor of recurrent VTE
when measured after the completion of 3–6 months of anticoagulation in
Management of Patients With Unprovoked Venous Marcucci et al. 231
patients with a first VTE. Individual studies [65–71] and meta-analyses
[16•,72,73] found a 2-fold higher risk of recurrence inpatientswith unprovoked
VTE who had an elevated (or positive) post-anticoagulation D-dimer than in
patients with a normal (or negative) D-dimer. Thus, a positive D-dimer con-
ferred an almost 9 % annual absolute risk for recurrent VTE (cumulative rate
30–35 % after five years) after the index event [16•]. A patient-level meta-anal-
ysis [16•] found that the prognostic utility of D-dimer was independent of pa-
tient age, timing of post-anticoagulation D-dimer testing, and the D-dimer cut-
point (250 or 500 ng/mL) used to define a positive/negative test. In one study,
D-dimer and RVO were jointly studied after stopping anticoagulation but only
D-dimer was an independent predictor of recurrent VTE [74].
In patients with a positive post-anticoagulation D-dimer, resumption of
anticoagulation should be considered given the associated higher risk for re-
current VTE [67]. In such circumstances an alternative approach is to repeat
the D-dimer measurement so as to reduce the potential for spuriously elevat-
ed levels and to base decisions on long-term anticoagulation on consistently
elevated D-dimer levels [75•]. Finally, there are limitations of D-dimer when
used in this clinical circumstance [64]. Ideally, D-dimer as a determinant of
recurrent VTE risk should be expressed as a continuous variable [76], but a
cut-point that dichotomizes patients’ risk for recurrent VTE (into low or high
risk groups) might be more useful in clinical practice. The drawback of this
approach is the potential need for assay-specific D-dimer cut-points [77].
In addition, even if the prognostic value of the D-dimer is independent of
patient age and comorbidity [78], D-dimer levels are higher, on average, in
the elderly [67] and age-specific D-dimer cut-points may increase its specific-
ity [77]. Age-specific D-dimer cut-points, as proposed for the diagnostic use
of D-dimer [79], may be helpful. Overall, additional research is needed to
identify the optimal manner in which D-dimer can be used as a predictor
of recurrent VTE.
Other global markers of coagulation activation, such as measures of
thrombin generation, have been assessed as predictors of recurrent VTE,
but are not yet ready for clinical use [80,81].
Clinical prediction guides for recurrent VTE
There are three CPGs that have been developed to stratify patients with trea-
ted unprovoked VTE as being at high or low risk for disease recurrence. The
Men and HER-DOO-2 CPG was the first such guide that was derived from a
prospective cohort of patients with a first unprovoked proximal DVT and/or
PE [82]. With this CPG, all men are considered at high risk of recurrence
(based on a 3 % annual risk threshold to define high risk). For women,
≥2 factors (comprising lower extremity hyperpigmentation, edema, redness,
D-dimer≥250 ng/mL [during anticoagulant therapy], obesity [body mass in-
dex ≥30 kg/m2], and age over 65 years) identifies women at high risk for re-
current VTE, whereas G2 factors identifies women at low (G3 % per year) risk
for recurrence [83••]. The Vienna CPG uses patient sex, VTE site/extension
and D-dimer (post-anticoagulation) to estimate an individual patient's risk
for recurrent VTE with the use of a nomogram and risk calculator [17••]. Fi-
nally, the DASH CPG, which comprises D-dimer (post-anticoagulation), pa-
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tient age, patient sex, and VTE occurring in association with hormonal ther-
apy, provides a numeric score corresponding to a risk for recurrent VTE based
on these four factors [84••]. Overall, although these CPGs may help clini-
cians in stratifying patients according to risk for recurrent VTE, they require
independent validation in separate patient populations [85].
Conclusion
In this review, we summarized key clinical and laboratory factors that confer
an increased risk for disease recurrence after a first unprovoked DVT or PE.
CPGs have been developed which combine these factors so as to classify
patients into high- or low-risk risk groups or to provide individualized esti-
mates for recurrence risk.
The CPGs that are developed to quantify the risk for recurrent VTE are
anchored on what is considered an 'acceptably low' rate of recurrence that
would justify stopping anticoagulation after 3–6 months of treatment
[86]. Based on data involving patients at low risk for recurrence (i.e.,
VTE provoked by a major risk factor), an annualized rate of approximately
3 % patient-year [82] (or a risk of 5 % at one year and 15 % at five years
[86]) has been proposed as a threshold below which most clinicians
would consider the risk of recurrence acceptably low so as to justify stop-
ping anticoagulation. Ideally, complementary CPGs should stratify patients
according to their risk for bleeding if anticoagulation is continued. To
date, few CPGs have estimated the anticoagulant-related risk of bleeding
in patients with VTE [87,88], and none addressed the risk during
long-term treatment. Although CPGs are available to predict bleeding in
patients with atrial fibrillation, such as the HAS-BLED score [89], these CPGs
have been developed in generally older populations than those with VTE.
The predicted rates of recurrent VTE and clinically important (or major)
bleeding should then be combined with an assessment of the clinical impact
of such events, which can be expressed by the case-fatality. Thus, in a large sys-
tematic review, the case-fatality rate for major bleeding during the initial three
months of anticoagulation for VTE was 11.3 % whereas the case-fatality rate
for recurrent VTE after at least 3 months of anticoagulant therapy was 3.6 %
[90,91,92••]. Finally, these objective factors should be combined with individ-
ual patients' values andpreferences regarding the need (or not) for ongoing anti-
coagulation in addition topractical factors such as treatment costs and feasibility
of anticoagulant monitoring [51].
Irrespective of whether a decision is made to continue or stop anticoagu-
lant therapy, such a decision should not be irreversible. Indeed, patients
should be reassessed periodically to re-evaluate their risk profile, to reassess
their preferences and to incorporate new research findings into individual pa-
tient management. For example, two recent randomized trials have shown
that patients with unprovoked VTE who take low-dose ASA (100 mg daily)
after completing anticoagulant therapy have a 25–30 % reduction in the risk
for recurrent VTE [93,94••]. Thus, ASA may be a long-term treatment option
in patients at intermediate risk for recurrence or those at higher risk for an-
ticoagulant-related bleeding. Additional prospective studies are needed to ex-
plore clinical management strategies which may include stopping
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anticoagulant therapy in patients at low risk, switching to ASA in patients at
intermediate risk for recurrence, and continuing anticoagulants in patients at
high risk for recurrent VTE.
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